CLAIMS

Claim 1. A pharmaceutical composition of an anti-IL-23p19 antibody hum13B8-b for use in the treatment of plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2; and

wherein a first dose of the pharmaceutical composition is to be subcutaneously administered to the patient on week 0, a second dose of the pharmaceutical composition is to be subcutaneously administered to the patient at 4 weeks, and a subsequent dose of the pharmaceutical composition is to be subcutaneously administered to the patient every 4 to 12 weeks thereafter.

Claim 2: The pharmaceutical composition according to claim 1, wherein the first dose of the pharmaceutical composition, the second dose of the pharmaceutical composition, and the subsequent dose of the pharmaceutical composition are the same.

Claim 3: The pharmaceutical composition according to claim 2, wherein the first dose of the pharmaceutical composition, the second dose of the pharmaceutical composition, and the subsequent dose of the pharmaceutical composition contain 100 mg hum13B8-b.

Claim 4: The pharmaceutical composition according to claim 1, wherein the subsequent dose of the pharmaceutical composition is to be administered every 12 weeks at least up to 16 weeks.

Claim 5: The pharmaceutical composition according to claim 1, wherein the subsequent dose of the pharmaceutical composition is to be administered every 4 weeks at least up to 28 weeks.

Claim 6: The pharmaceutical composition according to claim 1, wherein the subsequent dose of the pharmaceutical composition is to be administered every 12 weeks at least up to 40 weeks, at least up to 52 weeks, at least up to 72 weeks, or longer.

Claim 7: A pharmaceutical composition of an anti-IL-23p19 antibody hum13B8-b for use in the treatment of plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2; and

wherein the pharmaceutical composition results in an Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp) score of "clear" or "almost clear" with at least a 2-point reduction from the patient's baseline score after it is administered.

Claim 8: The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition further results in a significant improvement from the patient's baseline score for at least two of four parameters selected from the group consisting of: (i) Investigator Global Assessment (Scalp only) (IGA) score, (ii) Scalp Itch Numeric Rating Scale (NRS) score, (iii) Scalp Surface Area (SSA) score, and (iv) Psoriasis Scalp Severity Index (PSSI) score, after it is administered.

Claim 9: A pharmaceutical composition of an anti-IL-23p19 antibody hum13B8-b for use in the treatment of plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2; and

wherein the pharmaceutical composition results in a significant improvement from the patient's baseline score in an Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp) score after it is administered.

Claim 10: The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition further results in a significant improvement from the patient's baseline score for at least two of the four parameters selected from the group consisting of: (i) Investigator Global Assessment (Scalp only) (IGA) score, (ii) Scalp Itch Numeric Rating Scale (NRS) score, (iii) Scalp Surface Area (SSA) score, and (iv) Psoriasis Scalp Severity Index (PSSI) score, after it is administered.

Claim 11: A pharmaceutical composition of an anti-IL-23p19 antibody hum13B8-b for use in the treatment of plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2;

wherein a first dose of the pharmaceutical composition is to be subcutaneously administered to the patient on week 0, a second dose of the pharmaceutical composition is to be subcutaneously administered to the patient at 4 weeks, and a subsequent dose of the pharmaceutical composition is to be subcutaneously administered to the patient every 4 to 12 weeks thereafter, and

wherein the pharmaceutical composition results in an Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp) score of "clear" or "almost clear" with at least a 2-point reduction from the patient's baseline score after it is administered.

Claim 12: The pharmaceutical composition according to claim 11, wherein the pharmaceutical composition further results in a significant improvement from the patient's baseline score for the Psoriasis Scalp Severity Index (PSSI) after it is administered.

Claim 13: The pharmaceutical composition according to either claim 11 or 12, wherein the first dose of the pharmaceutical composition, the second dose of the pharmaceutical composition, and the subsequent dose of the pharmaceutical composition are same.

Claim 14: The pharmaceutical composition according to claim 13, wherein the first dose of the pharmaceutical composition, the second dose of the pharmaceutical composition, and the subsequent dose of the pharmaceutical composition contain 100 mg hum13B8-b.

Claim 15. Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for treating plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2; and

wherein a first dose of the medicament is to be subcutaneously administered to the patient on week 0, a second dose of the medicament is to be subcutaneously administered to the patient at 4 weeks, and a subsequent dose of the medicament is to be subcutaneously administered to the patient every 4 to 12 weeks thereafter.

Claim 16: The use according to claim 15, wherein the first dose of the medicament, the second dose of the medicament, and the subsequent dose of the medicament are the same.

Claim 17: The use according to claim 16, wherein the first dose of the medicament, the second dose of the medicament, and the subsequent dose of the medicament contain 100 mg hum13B8-b.

Claim 18: The use according to claim 15, wherein the subsequent dose of the medicament is to be administered every 12 weeks at least up to 16 weeks.

Claim 19: The use according to claim 15, wherein the subsequent dose of the medicament is to be administered every 4 weeks at least up to 28 weeks.

Claim 20: The use according to claim 15, wherein the subsequent dose of the medicament is to be administered every 12 weeks at least up to 40 weeks, at least up to 52 weeks, at least up to 72 weeks, or longer.

Claim 21: Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for treating plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2; and

wherein the medicament results in an Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp) score of "clear" or "almost clear" with at least a 2-point reduction from the patient's baseline score after it is administered.

Claim 22: The use according to claim 21, wherein the medicament further results in a significant improvement from the patient's baseline score for at least two of four parameters selected from the group consisting of: (i) Investigator Global Assessment (Scalp only) (IGA) score, (ii) Scalp Itch Numeric Rating Scale (NRS) score, (iii) Scalp Surface Area (SSA) score, and (iv) Psoriasis Scalp Severity Index (PSSI) score, after it is administered.

Claim 23: Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for treating plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2; and

wherein the medicament results in a significant improvement from the patient's baseline score in an Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp) score after it is administered.

Claim 24: The use according to claim 23, wherein the medicament further results in a significant improvement from the patient's baseline score for at least two of the four parameters selected from the group consisting of: (i) Investigator Global Assessment (Scalp only) (IGA) score, (ii) Scalp Itch Numeric Rating Scale (NRS) score, (iii) Scalp Surface Area (SSA) score, and (iv) Psoriasis Scalp Severity Index (PSSI) score, after it is administered.

Claim 25: Use of an anti-IL-23p19 antibody hum13B8-b in the manufacture of a medicament for treating plaque psoriasis of the scalp in a patient, wherein hum13B8-b comprises:

(i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and

(ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2;

wherein a first dose of the medicament is to be subcutaneously administered to the patient on week 0, a second dose of the medicament is to be subcutaneously administered to the patient at 4 weeks, and a subsequent dose of the medicament is to be subcutaneously administered to the patient every 4 to 12 weeks thereafter, and

wherein the medicament results in an Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp) score of "clear" or "almost clear" with at least a 2-point reduction from the patient's baseline score after it is administered.

Claim 26: The use according to claim 25, wherein the medicament further results in a significant improvement from the patient's baseline score for the Psoriasis Scalp Severity Index (PSSI) after it is administered.

Claim 27: The use according to either claim 25 or 26, wherein the first dose of the medicament, the second dose of the medicament, and the subsequent dose of the medicament are same.

Claim 28: The use according to claim 27, wherein the first dose of the medicament, the second dose of the medicament, and the subsequent dose of the medicament contain 100 mg hum13B8-b.